Anzeige
Meldung des Tages: Early Bird Special: Ad-hoc im Schatten einer milliardenschweren Entscheidung

Redhill Aktie (ADR) News

Aktie
WKN:  A40MF2 ISIN:  US7574683014 US-Symbol:  RDHL Branche:  Biotechnologie Land:  Israel
1,09 $
+0,00 $
0,00%
0,9300 € 01.05.26
Depot/Watchlist
Marktkapitalisierung *
32,25 Tsd. €
Streubesitz
-
KGV
-
Faktor
0.001
Originalaktie
IL0011223810

Redhill Biopharma Aktie (ADR) News

30.04.26 - PR Newswire
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-​related Crohn's Disease PR Newswire
27.04.26 - PR Newswire
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights PR Newswire
22.04.26 - PR Newswire
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-​Tumor Immunity in Triple-​Negative Breast Cancer in Preclinical Studies - New ...
25.02.26 - PR Newswire
Joint U.S. Commercialization of RedHill's Talicia® Commences
Joint U.S. Commercialization of RedHill's Talicia® Commences PR Newswire
05.01.26 - PR Newswire
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-​Related GI Side Effects PR Newswire
15.12.25 - PR Newswire
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells PR Newswire
01.12.25 - PR Newswire
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement PR Newswire
04.11.25 - PR Newswire
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement PR Newswire
22.10.25 - PR Newswire
RedHill Biopharma Receives Nasdaq Staff Determination Notification
RedHill Biopharma Receives Nasdaq Staff Determination Notification PR Newswire
20.10.25 - PR Newswire
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO PR Newswire
20.10.25 - PR Newswire
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-​Commercialization Partnership Deal PR Newswire
06.10.25 - PR Newswire
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® PR Newswire
29.09.25 - PR Newswire
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo PR Newswire
05.09.25 - PR Newswire
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights PR Newswire
20.08.25 - PR Newswire
RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win
RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win PR Newswire
18.08.25 - PR Newswire
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million PR Newswire
21.07.25 - PR Newswire
RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease
RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease PR Newswire
01.07.25 - PR Newswire
RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer PR Newswire
13.05.25 - PR Newswire
RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win
RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win PR Newswire
02.05.25 - PR Newswire
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress
RedHill-​Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress PR Newswire

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »
Anzeige

Aktie im Fokus

Mit Graphen gegen jede Abwehr
Plaid Technologies
0,396 €
+7,03%
Plaid Technologies Chart
Die Zukunft der Drohnen ist da
Mehr zur Aktie »